Emerging therapies for the treatment of ulcerative colitis.
Fiche publication
Date publication
mars 2020
Journal
Expert opinion on emerging drugs
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Pugliese N, Roda G, Peyrin-Biroulet L, Danese S
Lien Pubmed
Résumé
: Ulcerative colitis (UC) is a chronic idiopathic autoimmune inflammatory disorder, primarily affecting the gastrointestinal system. There are many patients affected that do not respond well to therapy and many others to which there is a loss of efficacy every year. The proportion of patients who have already experienced anti-TNF therapy is constantly increasing, making the development of new drugs with alternative mechanisms of action an important need for the treatment of UC.: This review aims on emerging drugs in the treatment of UC and reviews data on their efficacy and safety.: UC, for many years, comparatively to CD, received little attention for several possible reasons, especially because it was not considered as a progressive disease able to induce irreversible bowel damage. This has led to lower investments by the scientific community and a slower development of therapeutic options for UC. In the past few years, this trend has started to change. In fact, new promising drugs have been developed and others are emerging with positive results. Although many treatment modalities have recently been approved, additional drugs are currently being investigated and will probably be part of the UC treatment regimen in the coming years.
Mots clés
S1P modulators, emerging drugs, integrins blockers, janus kinase inhibitors, ulcerative colitis, Anti-IL23
Référence
Expert Opin Emerg Drugs. 2020 Mar 9;:1-9